Obesity: Super-Sized Medical Device Market

Obesity is a multi-hundred billion dollar market ready and waiting for device developers to catch up to fill an enormous unmet need. Between the low risk, low benefit drug options for overweight patients, and the high risk, high benefit surgeries for the morbidly obese, there's a huge gap in terms of therapies. This sweet spot covers a segement of over 50 million obese patients without weight loss options. Companies with new devices for obesity hope to serve that population; the market is existing and underserved, reimbursement risk is eliminated--since many patients will pay out of pocket to have weight loss procedures--so the remaining risk revolves around technology. However, technology risk in a multi-factorial disease whose mechanisms are poorly understood is significant.

By Mary Stuart

Blame it on our genes, super-sized food portions, or elastic waist bands—obesity has reached epidemic proportions in the Western world. For years it was overlooked, like the elephant in the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Policy & Regulation

More from Medtech Insight

Execs On The Move: 5-9 May 2025

 
• By 

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By 

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.